- CITATIONS: 1
|Application ||WB, E|
|Calculated MW||41109 Da|
|Antigen Region||21-50 aa|
|Other Names||Lysophosphatidic acid receptor 1, LPA receptor 1, LPA-1, Lysophosphatidic acid receptor Edg-2, LPAR1, EDG2, LPA1|
|Target/Specificity||This EDG2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 21-50 amino acids from the N-terminal region of human EDG2.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||EDG2 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Receptor for lysophosphatidic acid (LPA), a mediator of diverse cellular activities. Seems to be coupled to the G(i)/G(o), G(12)/G(13), and G(q) families of heteromeric G proteins. Stimulates phospholipase C (PLC) activity in a manner that is dependent on RALA activation.|
|Cellular Location||Cell surface. Cell membrane; Multi-pass membrane protein. Note=Prior to LPA treatment found predominantly at the cell surface but in the presence of LPA colocalizes with RALA in the endocytic vesicles|
|Tissue Location||Expressed in many adult organs, including brain, heart, colon, small intestine, placenta, prostate, ovary, pancreas, testes, spleen, skeletal muscle, and kidney. Little or no expression in liver, lung, thymus, or peripheral blood leukocytes|
Provided below are standard protocols that you may find useful for product applications.
The EDG2 integral membrane protein is a lysophosphatidic acid (LPA) receptor from a group known as EDG receptors. These receptors are members of the G protein-coupled receptor superfamily. Utilized by LPA for cell signaling, EDG receptors mediate diverse biologic functions, including proliferation, platelet aggregation, smooth muscle contraction, inhibition of neuroblastoma cell differentiation, chemotaxis, and tumor cell invasion.
Matsuda, A., et al., Oncogene 22(21):3307-3318 (2003).
Van Leeuwen, F.N., et al., J. Biol. Chem. 278(1):400-406 (2003).
Shida, D., et al., Cancer Res. 63(7):1706-1711 (2003).
Cervera, P., et al., Glia 38(2):126-136 (2002).
An, S., et al., Mol. Pharmacol. 54(5):881-888 (1998).
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.